TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06308588: Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Sponsor: M.D. Anderson Cancer Center · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06308588 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06308588 Rescue Dossier →